What is Cardiac Amyloidosis?
Cardiac amyloidosis is a rare disease that occurs when abnormal proteins, called amyloid, build up in the heart muscle. This can lead to heart failure, a condition in which the heart can’t pump enough blood to meet the body’s needs.
How Does Vutrisiran Work?
Vutrisiran is a medication that works by targeting and reducing the production of the abnormal protein that causes cardiac amyloidosis. It is administered as an injection under the skin every three months.
Clinical Trial Results
Clinical trials have shown that Vutrisiran can significantly improve heart function in people with cardiac amyloidosis. In one study, patients who received Vutrisiran had a 46% reduction in the thickness of their heart walls, compared to a 13% reduction in patients who received a placebo.
Vutrisiran has also been shown to improve symptoms of cardiac amyloidosis, such as shortness of breath, fatigue, and chest pain. In another study, patients who received Vutrisiran had a 40% improvement in their quality of life, compared to a 10% improvement in patients who received a placebo.
Benefits of Vutrisiran
The benefits of Vutrisiran for people with cardiac amyloidosis include:
- Improved heart function
- Reduced symptoms
- Improved quality of life
- Slowed progression of the disease
Possible Side Effects
Common side effects of Vutrisiran include:
- Injection site reactions
- Headache
- Nausea
- Dizziness
Serious side effects are rare.
Who Should Consider Vutrisiran?
Vutrisiran is an important treatment option for people with cardiac amyloidosis. It can help to improve heart function, reduce symptoms, and improve quality of life. If you have been diagnosed with cardiac amyloidosis, talk to your doctor about whether Vutrisiran is right for you.
Kind regards
F. Hillsom
